Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 12/20 | 0.53 |
| ▸ | AURKA | O14965 | 7/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 11/20 | 0.44 |
| ▸ | LCK | P06239 | 7/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14529984 | 0.91 | CHEK1 (0.44) | AURKBAURKAPTK6CHEK1 | |
| SCHEMBL8241447 | 0.91 | CHEK1 (0.44) | AURKBAURKAPTK6CHEK1 | |
| SCHEMBL8246925 | 0.82 | CHEK1 (0.46) | AURKBAURKAPTK6LCKCHEK1 | |
| SCHEMBL8241422 | 0.82 | CHEK1 (0.61) | AURKBAURKAPTK6LCKCHEK1 | |
| SCHEMBL14507767 | 0.81 | CHEK1 (0.47) | AURKBAURKAPTK6CHEK1 | |
| SCHEMBL8241616 | 0.81 | AURKA (0.64) | AURKBAURKA | |
| SCHEMBL8428012 | 0.80 | AURKA (0.47) | AURKBAURKAPTK6CHEK1 | |
| SCHEMBL8241480 | 0.80 | AURKA (0.49) | AURKBAURKAPTK6LCKCHEK1 | |
| SCHEMBL8248043 | 0.80 | PIK3CD (0.44) | AURKBAURKAPTK6LCK | |
| SCHEMBL8247986 | 0.79 | AURKA (0.45) | AURKBAURKAPTK6CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | AURKB 3/4885AURKA 2/4885PTK6 840/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKB 137/4885AURKA 91/4885PTK6 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.